A world leading health company is seeking novel antibiotic-free microbial expression systems for production of a wide range of biologics including recombinant proteins, peptides, antigens, Fc-fusion proteins, and monoclonal antibodies. Additionally, the team is looking for partners and/or technologies to support removal of AMR genes from bacterial genomes through genetic modification. Approaches of Interest: <ul> <li>Bacterial or cell-based expression systems that are cost-effective, produce a high biologic yield and have scalable manufacturing capability are of...</li></ul>

A leading health company is seeking  antibiotic-free microbial expression systems for production of biologics including recombinant proteins and peptides, as well as seeking technologies to support removal of AMR genes from bacterial genomes.

Antibiotic-free Microbial Expression and Genetic Systems

An immunology&#x2011;focused pharmaceutical company is seeking novel druggable targets and/or molecules that are involved in regulation of immunometabolism in inflammatory disease. Specifically, the team are looking to focus on targetable molecules with demonstrated involvement in human pathology (e.g. a role in pathways linked to disease). Approaches of Interest: <ul> <li>Approaches that dramatically alter the immune cell state (e.g. macrophage M1 to M2 transition, or Th1 to Treg transition)</li> <li>Targets that specifically express in immune cells</li> <li>Improved modulation of pathways...</li></ul>

An immunology-focused pharmaceutical company is seeking druggable targets and/or molecules involved in metabolic regulation of immune function, with a specific focus on targetable molecules with demonstrated involvement in human pathology.

Seeking Novel Approaches for Regulating Immunometabolism in the Treatment of Inflammatory Diseases 

The field of targeted therapeutic radioconjugates is rapidly expanding, promising significant advancements in cancer treatment. In contrast to antibodies, radioconjugates benefit from shorter half-lives, minimizing radiation toxicity to healthy tissues. With a focus on binders of low molecular weight (&lt; 50 kDa), such as small molecules, peptides, and antibody fragments, these radioconjugates demonstrate rapid renal clearance, albeit with an increased likelihood of elevated kidney retention based on their physicochemical characteristics. AstraZeneca has ...

EXTENSION - AstraZeneca is seeking a higher-throughput assay to predict kidney retention through in vitro cells or organoid models.

Predictive in vitro Assays for Kidney Retention by Radioconjugates

AstraZeneca is seeking a higher-throughput assay to predict kidney retention of radioconjugates through in vitro cells or organoid models.  

Engage with world leading R&D teams

Active campaigns

ico

Antibiotic-free Microbial Expression and Genetic Systems

ico

Seeking Novel Approaches for Regulating Immunometabolism in the Treatment of Inflammatory Diseases

Previous campaigns

rfp

Predictive in vitro Assays for Kidney Retention by Radioconjugates

rfp

Predictive in vitro Assays for Kidney Retention by Radioconjugates

Trusted by